Genevieve Laforet to Female
This is a "connection" page, showing publications Genevieve Laforet has written about Female.
Connection Strength
0.053
-
Kiefer M, Khan A, Leiro B, Yavorsky C, Laforet G, Kirby K, Townsend E. Feasibility, Acceptability, and Reliability of Remote Motor Assessment in Children With Canavan Disease. Pediatr Neurol. 2025 Mar; 164:129-136.
Score: 0.013
-
Nagy A, Eichler F, Bley A, Bredow J, Fay A, Townsend EL, Leiro B, Shaywitz A, Laforet G, Crippen-Harmon D, Williams R. Urine N-Acetylaspartate Distinguishes Phenotypes in Canavan Disease. Hum Gene Ther. 2024 Jan; 36(1-2):45-56.
Score: 0.013
-
Varsanik JS, Kimmel ZM, Laforet GA, Ricotti V, Sajeev G, Signorovitch J, Quiroz JA, Chevalier TW. Validation of an ambient measurement system (AMS) for physical activities in a paediatric population. J Med Eng Technol. 2019 Apr; 43(3):182-189.
Score: 0.009
-
Llano DA, Laforet G, Devanarayan V. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Jan-Mar; 25(1):73-84.
Score: 0.005
-
Apostol G, Pakalnis A, Laforet GA, Robieson WZ, Olson E, Abi-Saab WM, Saltarelli M. Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents. Headache. 2009 Jan; 49(1):36-44.
Score: 0.004
-
Apostol G, Lewis DW, Laforet GA, Robieson WZ, Fugate JM, Abi-Saab WM, Saltarelli MD. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. Headache. 2009 Jan; 49(1):45-53.
Score: 0.004
-
Apostol G, Cady RK, Laforet GA, Robieson WZ, Olson E, Abi-Saab WM, Saltarelli M. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache. 2008 Jul; 48(7):1012-25.
Score: 0.004